Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06232083
Other study ID # Zhou peijie-2024ky-02
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 1, 2024
Est. completion date February 1, 2026

Study information

Verified date January 2024
Source Anhui Provincial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

At present, the treatment methods for recurrent cervical cancer are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent cervical cancer, but the clinical response rate is insufficient. Pulse low-dose rate radiotherapy (PLDR) is a new technology in recent years, which uses continuous pulse low-dose rate irradiation to induce hypersensitivity in tumors, and its clinical safety has been verified. Compared to conventional radiotherapy, PLDR has advantages in protecting the lymphatic system and relieving the immune barrier, but it is still unclear whether it can improve the efficacy of ICB. This project aims to combine PLDR with ICB to explore new strategies for recurrent cervical cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 33
Est. completion date February 1, 2026
Est. primary completion date February 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: 1. Voluntarily participate and sign an informed consent form in writing; 2. Age 20-70 years old, ECOG score 0-2 points; 3. Newly diagnosed metastatic cervical squamous cell carcinoma or adenocarcinoma patients who have been assessed as unsuitable or have refused chemotherapy; 4. Cervical squamous cell carcinoma or adenocarcinoma patients who experience recurrence and metastasis after regular treatment (local recurrence should be ruled out by surgery); 5. Laboratory examination: White blood cells = 3.0 × 109/L; Hemoglobin = 90 g/L; Number of neutrophils = 1.5 × 109/L; Platelets = 100 × 109/L; The liver and kidney function, thyroid function, and other indicators are all within the range of 1.25 times the upper normal limit value; Normal coagulation function; The indicators of cardiac troponin and myocardial enzyme spectrum are normal, and the electrocardiogram is normal. 6. The expected survival period is more than 6 months and the follow-up conditions are met; 7. Patients are able to coordinate positioning and receive long-term treatment; 8. Previous radiation therapy information can be obtained, such as the total dose of the target area, segmentation mode, dose distribution, and normal tissue dose; 9. For patients with recurrent cervical cancer, the initial irradiation dose (external irradiation+close range irradiation) is safe and well tolerated after EQD2 calculation. Exclusion Criteria: 1. Elderly patients (>70 years old); 2. ECOG score = 3 points; 3. The pathological type is adenocarcinoma or other rare cervical cancer; 4. Those diagnosed with severe liver and lung metastasis, malignant pleural and ascitic fluid, complete intestinal obstruction, and other extremely poor expected survival through imaging; 5. The patient is accompanied by severe ureteral stenosis, hematuria, or bladder vaginal fistula; 6. Has a history of severe allergies or specific physical conditions; 7. Diagnosed as immunodeficiency or presence of active hepatitis B and C, active tuberculosis; 8. Patients with missing initial external irradiation information and inability to estimate dose; 9. Patients who have not signed informed consent or are unwilling to undergo follow-up; 10. Patients with a disease-free survival time of less than 3 months or who have received routine radiation within the past six months.

Study Design


Intervention

Radiation:
PLDR+Cardunizumab
Application of PLDR external irradiation combined with Cardunizumab in recurrent cervical cancer

Locations

Country Name City State
China The First Affiliated Hospital of University of Science and Technology of China Hefei British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Anhui Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS Progression-free survival 6 month post PLDR external irradiation
Secondary Toxic side effects 6 month post PLDR external irradiation
See also
  Status Clinical Trial Phase
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06165900 - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT06262581 - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting NCT04372732 - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Not yet recruiting NCT06012318 - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting NCT05479240 - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT04711330 - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting NCT03683407 - Effect of Chemotherapy on TMB in NSCLC
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Completed NCT03357861 - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting NCT05223088 - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Phase 2
Completed NCT05657262 - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas N/A